Guggenheim Highlights Growth Potential in Johnson & Johnson (JNJ), Maintains Buy

Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Stocks to Buy for the Long Term.

Guggenheim Highlights Growth Potential in Johnson & Johnson (JNJ), Maintains Buy

On December 5, Guggenheim boosted the firm’s price target on Johnson & Johnson (NYSE:JNJ) to $227 from $206 and maintained a Buy rating on the shares. According to the analyst research note, the update came after the firm reviewed the company’s model and noted “multiple drivers of additional upside” going into 2026.

In addition to being a strong pharmaceutical company, Johnson & Johnson (NYSE:JNJ) is also taking strategic steps to enhance its operations. In October, the company announced plans to separate its orthopedics division as a standalone company named DePuy Synthes within 18-24 months. Previously, JNJ also spun off its consumer healthcare division, which now operates as Kenvue. These key initiatives are part of the company’s plan to focus on more high-growth areas to broaden its reach.

In addition, Johnson & Johnson (NYSE:JNJ)’s announcement to acquire Halda Therapeutics for $3.05 billion is also a step to strengthen its already extensive portfolio of oncology drugs. It will also help encounter some of the competitive pressure it is facing in its oncology and immunology portfolio, including drugs like Tremfya. JNJ’s competitors, including AbbVie, offer comparable treatments and have been steadily capturing market shares from JNJ.

While we acknowledge the potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 11 Worst Performing Dividend Stocks Year-to-Date.

Disclosure: None.